Enhanc3D Genomics appoints Hazel Jones as CEO

Enhanc3D Genomics has announced the appointment of Hazel Jones as chief executive officer (CEO), following a successful six-month term as interim CEO and COO.
In her interim role, Hazel oversaw the company’s global business operations and was responsible for its commercial and academic partnerships.
Hazel has over ten years of senior leadership within oncology research, covering all phases of the drug development process from target validation to clinical development.
Dr Chris Torrance, chairman of Enhanc3D Genomics’ board of directors, stated: “We're thrilled to officially appoint Hazel as CEO. Her guidance as COO and interim CEO has been instrumental in driving
Enhanc3D Genomics’ global operations, forming new connections and developing existing strategic partnerships. On behalf of the board, I congratulate Hazel and look forward to continuing to work with her during this exciting phase for the Company.”
Commenting on her appointment, Dr Hazel Jones, added: “My time as COO and interim CEO has been highly rewarding, and I am now honoured and excited to have been appointed to continue to lead Enhanc3D Genomics as CEO. Iam grateful for the trust placed in me by the Board and look forward to continuing to lead the company through our pivotal transition period to full commercialisation of our 3D genomics platform.”